Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Extrapolated Biosimilar Indications Won't Get More Post-Marketing Requirements

Executive Summary

Biosimilars will have same pharmacovigilance expectations as innovator biologics despite lack of clinical data for some extrapolated indications.

You may also be interested in...



Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway

Time and again, FDA officials had to explain the importance of the analytical characterization data in the biosimilar development paradigm.

Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway

Time and again, FDA officials had to explain the importance of the analytical characterization data in the biosimilar development paradigm.

FDA Sets New Goal For Biosimilar, Drug Promotion Guidances

Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS057449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel